Cortical selective vulnerability in motor neuron disease: A morphometric study

Brain

Volumn 127, Issue 6, 2004, Pages 1237-1251

  Maekawa, S ^a   Al Sarraj, S ^a   Kibble, M ^a   Landau, S ^b   Parnavelas, J ^a   Cotter, D ^c   Everall, I ^a   Leigh, P Nigel ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Anterior cingulate cortex; Dorsolateral prefrontal cortex; Motor neuron disease; Primary motor cortex; Selective vulnerability

Indexed keywords

ANTIBODY; CALBINDIN; CALCIUM BINDING PROTEIN; CALRETININ; EPITOPE; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN HEAVY CHAIN; PARVALBUMIN; SMI 32 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTERIOR CINGULATE CORTEX; ARTICLE; CELL DENSITY; CINGULATE GYRUS; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HUMAN; HUMAN TISSUE; INTERNEURON; MALE; MOTOR CORTEX; MOTOR NEURON DISEASE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; QUANTITATIVE ANALYSIS;

AGED; ANTIBODIES, MONOCLONAL; CALCIUM-BINDING PROTEINS; CELL COUNT; CELL SIZE; CEREBRAL CORTEX; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; INTERNEURONS; MALE; MIDDLE AGED; MOTOR CORTEX; MOTOR NEURON DISEASE; MOTOR NEURONS; NEUROFILAMENT PROTEINS; PREFRONTAL CORTEX; PYRAMIDAL CELLS;

EID: 2942532727     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh132     Document Type: Article

References (100)

1. Abercrombie M. Estimation of nuclear population from microtomic sections. Anat Rev 1946; 94: 239.
2. Abrahams S, Leigh PN, Kew JJ, Goldstein LH, Lloyd CM, Brooks DJ. A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis. J Neurol Sci 1995; 129 Suppl: 44-6.
3. Abrahams S, Goldstein LH, Kew JJ, Brooks DJ, Lloyd CM, Frith CD, et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain 1996; 119: 2105-20.
4. Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grise D, Goldstein LH. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia 2000; 38: 734-47.
5. Al-Sarraj S, Maekawa S, Kibble M, Everall I, Leigh PN. Ubiquitin-only intraneuronal inclusion in the substantia nigra is a characteristic feature of motor neuron disease with dementia. Neuropathol Appl Neurobiol 2002; 28: 120-8.
6. Bak TH, Hodges JR. Cognition, language and behaviour in motor neurone disease: evidence of frontotemporal dysfunction. [Review]. Dement Geriatr Cogn Disord 1999; 10 Suppl 1: 29-32.
7. Baleydier C, Achache P, Froment JC. Neurofilament architecture of superior and mesial premotor cortex in the human brain. Neuroreport 1997; 8: 1691-6.
8. Barr ML, Hamilton JD. A quantitative study of certain morphological changes in spinal motor neurons during axon reaction. J Comp Neurol 1948; 89: 93-121.
9. Benes FM, Lange N. Two-dimensional versus three-dimensional cell counting: a practical perspective. Trends Neurosci 2001; 24: 11-7.
10. Bergmann M. Motor neuron disease/amyotrophic lateral sclerosis-lessons from ubiquitin. Pathol Res Pract 1993; 189: 902-12.
11. Brodal P. Cerebral cortex. In: Brodal P. The central nervous system: structure and function. New York: Oxford University Press; 1992. p. 398-424.
12. Brownell B, Oppenheimer DR, Hughes JT. The central nervous system in motor neurone disease. J Neurol Neurosurg Psychiatry 1970; 33: 338-57.
13. Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B. Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 2002; 28: 283-91.
14. Campbell MJ, Morrison JH. Monoclonal antibody to neurofilament protein (SMI-32) labels a subpopulation of pyramidal neurons in the human and monkey neocortex. J Comp Neurol 1989; 282: 191-205.
15. Caramia MD, Palmieri MG, Desiato MT, Iani C, Scalise A, Telera S, et al. Pharmacologic reversal of cortical hyperexcitability in patients with ALS. Neurology 2000; 54: 58-64.
16. Carriedo SG, Yin HZ, Lamberta R, Weiss JH. In vitro kainate injury to large, SMI-32(+) spinal neurons is Ca2+ dependent. Neuroreport 1995; 6: 945-8.
17. Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci 1996; 16: 4069-79.
18. Celio MR. Calbindin D-28k and parvalbumin in the rat nervous system. Neuroscience 1990; 35: 375-475.
19. Celio MR, Baier W, Scharer L, Gregersen HJ, de Viragh PA, Norman AW. Monoclonal antibodies directed against the calcium binding protein Calbindin D-28k. Cell Calcium 1990; 11: 599-602.
20. Chari G, Shaw PJ, Sahgal A. Nonverbal visual attention, but not recognition memory of learning, processes are impaired in motor neurone disease. Neuropsychologia 1996; 34: 377-85.
21. Chou SM. Pathology of motor system disorder. In: Leigh PN, Swash M, editors. Motor neuron disease. London: Springer-Verlag; 1995. p. 53-92.
22. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. [Review]. Nat Rev Neurosci 2001; 2: 806-19.
23. Comoletti D, Muzio V, Capobianco A, Ravizza T, Mennini T. Nitric oxide produced by non-motoneuron cells enhances rat embryonic motoneuron sensitivity to excitotoxins: comparison in mixed neuron/glia or purified cultures. J Neurol Sci 2001; 192: 61-9.
24. Cotter D, Landau S, Beasley C, Stevenson R, Chana G, MacMillan L, et al. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry 2002; 51: 377-86.
25. Cudkowicz M, Kowall NW. Degeneration of pyramidal projection neurons in Huntington's disease cortex. Ann Neurol 1990; 27: 2004.
26. David AS, Gillham RA. Neuropsychological study of motor neuron disease. Psychosomatics 1986; 27: 441-5.
27. Davison C. Amyotrophic lateral sclerosis: origin and extent of the upper motor neuron lesion. Arch Neurol Psychiatry 1941; 46: 1039-56.
28. DeFelipe J. Types of neurons, synaptic connections and chemical characteristics of cells immunoreactive for calbindin-D28K, parvalbumin and calretinin in the neocortex. [Review]. J Chem Neuroanat 1997; 14: 1-19.
29. Del Río MR, DeFelipe J. A study of SMI 32-stained pyramidal cells, parvalbumin-immunoreactive chandelier cells, and presumptive thalamocortical axons in the human temporal neocortex. J Comp Neurol 1994; 342: 389-408.
30. Demeulemeester H, Vandesande F, Orban GA, Brandon C, Vanderhaeghen JJ. Heterogeneity of GABAergic cells in cat visual cortex. J Neurosci 1988; 8: 988-1000.
31. Eisen A. Clinical electrophysiology of the upper and lower motor neuron in amyotrophic lateral sclerosis. [Review]. Semin Neurol 2001; 21: 141-54.
32. Ellis CM, Suckling J, Amaro E Jr, Bullmore ET, Simmons A, Williams SC, et al. Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology 2001; 57: 1571-8.
33. Ferrer I, Tunon T, Serrano MT, Casas R, Alcantara S, Zujar MJ, et al. Calbindin D-28k and parvalbumin immunoreactivity in the frontal cortex in patients with frontal lobe dementia of non-Alzheimer type associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 257-61.
34. Ferrer I, Olive M, Rivera R, Pou A, Narberhaus B, Ugarte A. Hereditary spastic paraparesis with dementia, amyotrophy and peripheral neuropathy. A neuropathological study. Neuropathol Appl Neurobiol 1995; 21: 255-61.
35. Gallassi R, Montagna P, Ciardulli C, Lorusso S, Mussuto V, Stracciari A. Cognitive impairment in motor neuron disease. Acta Neurol Scand 1985; 71: 480-4.
36. Ginsberg SD, Martin LJ, Rothstein JD. Regional deafferentation down-regulates subtypes of glutamate transporter proteins. J Neurochem 1995; 65: 2800-3.
37. Gredal O, Pakkenberg H, Karlsborg M, Pakkenberg B. Unchanged total number of neurons in motor cortex and neocortex in amyotrophic lateral sclerosis: a stereological study. J Neurosci Methods 2000; 95: 171-6.
38. Greene JR, Radenahmad N, Wilcock GK, Neal JW, Pearson RC. Accumulation of calbindin in cortical pyramidal cells with ageing; a putative protective mechanism which fails in Alzheimer's disease. Neuropathol Appl Neurobiol 2001; 27: 339-42.
39. Hammer RP Jr, Tomiyasu U, Scheibel AB. Degeneration of the human Betz cell due to amyotrophic lateral sclerosis. Exp Neurol 1979; 63: 336-46.
40. Hedreen JC. Lost caps in histological counting methods. Anat Rec 1998; 250:366-72.
41. Heizmann CW, Braun K. Changes in Ca(2+)-binding proteins in human neurodegenerative disorders. [Review]. Trends Neurosci 1992; 15: 259-64.
42. Hof PR, Cox K, Morrison JH. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex. J Comp Neurol 1990; 301: 44-54.
43. Hof PR, Nimchinsky EA, Buee-Scherrer V, Buee L, Nasrallah J, Hottinger AF, et al. Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders. Acta Neuropathol (Berl) 1994; 88: 397-404.
44. Hof PR, Ungerleider LG, Webster MJ, Gattass R, Adams MM, Sailstad CA, et al. Neurofilament protein is differentially distributed in subpopulations of corticocortical projection neurons in the macaque monkey visual pathways. J Comp Neurol 1996; 376: 112-27.
45. Hof PR, Duan H, Page TL, Einstein M, Wicinski B, He Y, et al. Age-related changes in GluR2 and NMDARI glutamate receptor subunit protein immunoreactivity in corticocortically projecting neurons in macaque and patas monkeys. Brain Res 2002; 928: 175-86.
46. Hughes JT. Pathology of amyotrophic lateral sclerosis. Adv Neurol 1982; 36: 61-74.
47. Ince P, Stout N, Shaw P, Slade J, Hunziker W, Heizmann CW, Baimbridge KG. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol 1993; 19: 291-9.
48. Ince PG, Shaw PJ, Slade JY, Jones C, Hudgson P. Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. [Review]. Acta Neuropathol (Berl) 1996; 92: 395-403.
49. Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. [Review]. Neuropathol Appl Neurobiol 1998; 24: 104-17.
50. Jackson M, Lennox G, Lowe J. Motor neurone disease-inclusion dementia. Neurodegeneration 1996; 5: 339-350.
51. Kew JJM, Leigh PN. Dementia with motor neuron disease. In: Rossor M, editor. Unusual Dementias. Baillière's clinical neurology, Vol. 1, No. 3. London: Baillière Tindall; 1992. pp. 611-26.
52. Kew JJ, Goldstein LH, Leigh PN, Abrahams S, Cosgrave N, Passingham RE, et al. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain 1993a; 116: 1399-423.
53. Kew JJ, Leigh PN, Playford ED, Passingham RE, Goldstein LH, Frackowiak RS, Brooks DJ. Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. Brain 1993b; 116: 655-80.
54. Kiernan JA, Hudson AJ. Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. Brain 1991; 114: 843-53.
55. Kiernan JA, Hudson AJ. Changes in shapes of surviving motor neurons in amyotrophic lateral sclerosis. Brain 1993; 116: 203-15.
56. Kondo H, Tanaka K, Hashikawa T, Jones EG. Neurochemical gradients along monkey sensory cortical pathways: calbindin-immunoreactive pyramidal neurons in layers II and III. Eur J Neurosci 1999; 11: 4197-203.
57. Lassek AM. The human pyramidal tract: 11. A numerical investigation of the Betz cells of the motor area. Arch Neurol Psychiatry 1940; 44: 718-24.
58. Leigh PN, Meldrum BS. Excitotoxicity in ALS. [Review]. Neurology 1996; 47 (6 Suppl 4): S221-7.
59. Leigh PN, Simmons A, Williams S, Williams V, Turner M, Brooks D. Imaging: MRS/MRI/PET/SPECT: summary. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3 Suppl 1: S75-80.
60. Lloyd CM, Richardson MP, Brooks DJ, Al-Chalabi A, Leigh PN. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain 2000; 123: 2289-96.
61. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003: 60: 1094-7.
62. Ludolph AC, Langen KJ, Regard M, Herzog H, Kemper B, Kuwert T, et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand 1992; 85: 81-9.
63. Macdonald V, Halliday GM, Trent RJ, McCusker EA. Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease. Neuropathol Appl Neurobiol 1997; 23: 492-5.
64. Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. [Review]. Arch Neurol 2001; 58: 365-70.
65. Massman PJ, Sims J, Cooke N, Haverkamp LJ, Appel V, Appel SH. Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1996; 61: 450-5.
66. Mesulam M, Geula C. Differential distribution of a neurofilament protein epitope in acetylcholinesterase-rich neurons of human cerebral neocortex. Brain Res 1991; 544: 169-73.
67. Morrison JH, Lewis DA, Campbell MJ, Huntley GW, Benson DL, Bouras C. A monoclonal antibody to non-phosphorylated neurofilament protein marks the vulnerable cortical neurons in Alzheimer's disease. Brain Res 1987; 416: 331-6.
68. Munoz DG, Greene C, Perl DP, Selkoe DJ. Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol 1988; 47: 9-18.
69. Murakami T. Motor neuron disease: quantitative morphological and microdensitophotometric studies of neurons of anterior horn and ventral root of cervical spinal cord with special reference to the pathogenesis. J Neurol Sci 1990; 99: 101-15.
70. Murayama S, Bouldin TW, Suzuki K. Immunocytochemical and ultrastructural studies of upper motor neurons in amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 1992; 83: 518-24.
71. Nakano I. Frontotemporal dementia with motor neuron disease (amyotrophic lateral sclerosis with dementia). [Review]. Neuropathology 2000; 20: 68-75.
72. Nihei K, McKee AC, Kowall NW. Degeneration of non pyramidal local circuit neurons in the motor cortex of amyotrophic lateral sclerosis patients [abstract]. J Neuropathol Exp Neurol 1992; 51: 322.
73. Nihei K, McKee AC, Kowall NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol (Berl) 1993; 86: 55-64
74. Nyberg-Hansen R, Rinvik E. Some comments on the pyramidal tract, with special reference to its individual variations in man. Acta Neurol Scand 1963; 39: 1-30.
75. Okamoto K, Murakami N, Kusaka H, Yoshida M, Hashizume Y, Nakazato Y, et al. Ubiquitin-positive intraneuronal inclusions in the extramotor cortices of presenile dementia patients with motor neuron disease. J Neurol 1992; 239: 426-30.
76. Petrides M, Pandya DN. Dorsolateral prefrontal cortex: comparative cytoarchitectonic analysis in the human and the macaque brain and corticocortical connection patterns. Eur J Neurosci 1999; 11: 1011-36
77. Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. [Review]. Adv Neurol 1995; 68: 7-20.
78. Rothstein JD. Excitotoxicity hypothesis. [Review]. Neurology 1996; 47 (4 Suppl 2): S19-25.
79. Saroff D, Delfs J, Kuznetsov D, Geula C. Selective vulnerability of spinal cord motor neurons to non-NMDA toxicity. Neuroreport 2000; 11: 1117-21.
80. Sasaki S, Maruyama S. Immunocytochemical and ultrastructural studies of the motor cortex in amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 1994; 87: 578-85.
81. Shaw PJ. Excitotoxicity and motor neurone disease: a review of the evidence. [Review]. J Neurol Sci 1994; 124 Suppl: 6-13.
82. Shaw PJ, Ince PG. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. [Review]. J Neurol 1997; 244 (Suppl 2): S3-14.
83. Sommer M, Tergau F, Wischer S, Reimers CD, Beuche W, Paulus W. Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis. J Neurol 1999: 246 Suppl 3: I1122-6.
84. Stefan K, Kunesch E, Benecke R, Classen J. Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis. Ann Neurol 2001; 49: 536-9.
85. Sternberger LA. Immunocytochemistry. 3rd ed. New York: Wiley; 1985.
86. Strong MJ, Grace GM, Orange JB, Leeper HA, Menon RS, Aere C. A prospective study of cognitive impairment in ALS. Neurology 1999; 53: 1665-70.
87. Troost D, Sillevis Smitt PA, de Jong JM, Swaab DF. Neurofilament and glial alterations in the cerebral cortex in amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 1992; 84: 664-73.
88. Tsang YM, Chiong F, Kuznetsov D, Kasarskis E, Geula C. Motor neurons are rich in non-phosphorylated neurofilaments: cross-species comparison and alterations in ALS. Brain Res 2000; 861: 45-58.
89. Udaka F, Kameyama M, Tomonaga M. Degeneration of Betz cells in motor neuron disease. A Golgi study. Acta Neuropathol (Berl) 1986; 70: 289-95.
90. Urushitani M, Shimohama S, Kihara T, Sawada H, Akaike A, Ibi M, et al. Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: involvement of glutamate-induced nitric oxide in motor neuron toxicity and nonmotor neuron protection. Ann Neurol 1998; 44: 796-807.
91. Vandenberghe W, Robberecht W, Brorson JR. AMPA receptor calcium permeability, GluR2 expression, and selective motoneuron vulnerability. J Neurosci 2000a; 20: 123-32.
92. Vandenberghe W, Ihle EC, Patneau DK, Robberecht W, Brorson JR. AMPA receptor current density, not desensitization, predicts selective motoneuron vulnerability. J Neurosci 2000b; 20: 7158-66.
93. Vandenberghe W, Bindokas VP, Miller RJ, Robberecht W, Brorson JR. Subcellular localization of calcium-permeable AMPA receptors in spinal motoneurons. Eur J Neurosci 2001; 14: 305-14.
94. Vogt BA, Nimchinsky EA, Vogt LJ, Hof PR. Human cingulate cortex: surface features, flat maps, and cytoarchitecture. J Comp Neurol 1995; 359: 490-506.
95. Wightman G, Anderson VE, Martin J, Swash M, Anderton BH, Neary D, et al. Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia. Neurosci Lett 1992; 139: 269-74.
96. Young AB, Bromberg MB, Penney JB Jr. Decreased glutamate uptake in subcortical areas deafferented by sensorimotor cortical ablation in the cat. J Neurosci 1981; 1: 241-9.
97. Zanette G, Tamburin S, Manganotti P, Refatti N, Forgione A, Rizzuto N. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin Neurophysiol 2002a; 113: 1688-97.
98. Zanette G, Tamburin S, Manganotti P, Refatti N, Forgione A, Rizzuto N. Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis. J Neurol 2002b; 249: 1723-8.
99. Zeman S, Lloyd C, Meldrum B, Leigh PN. Excitatory amino acids, free radicals and the pathogenesis of motor neuron disease. [Review]. Neuropathol Appl Neurobiol 1994; 20: 219-31.
100. Ziemann U, Winter M, Reimers CD, Reimers K, Tergau F, Paulus W. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology 1997; 49: 1292-8.